ARCHIVES

Tasigna Shows Benefit Over Gleevec In Phase III Study for Ph+ CML In Chronic Phase

This article is from The Cancer Letter archive.

Vol. 33 No. 12 | December 31, 2010

Download PDF Visit The Full Archive

Related Articles

Crout, Finkel Replaced at FDA; Hayes Combine Biologics, Drugs

April 2, 1982

Vermont Cancer Center’s NCI Core Grant Renewed.

May 11, 2001

In Brief: Hong to Retire After 30 Years at MD Anderson

February 14, 2014

Seven Divisions Proposed, Separating Intramural, Extramural Programs

August 11, 1995

It’s Official : PRI Wins Massive FCRF Contract ; DMS Keeps Library, Lands Computer Servicea

September 18, 1987

FDA Advisors Recommend Use of Cytokines GM-CSF, G-CSF In BMT And Chemotherapy

January 4, 1991